Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $51.21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $51.21.

A number of equities research analysts have recently commented on the stock. Guggenheim increased their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Oppenheimer upped their price objective on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th. Wells Fargo & Company upped their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Truist Financial reissued a “buy” rating and issued a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Finally, UBS Group dropped their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday, November 4th.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $48.63 on Friday. The company has a fifty day moving average of $47.21 and a two-hundred day moving average of $41.49. Kymera Therapeutics has a fifty-two week low of $15.95 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) earnings per share. As a group, sell-side analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its position in Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the last quarter. Comerica Bank boosted its position in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares in the last quarter. Keudell Morrison Wealth Management boosted its position in shares of Kymera Therapeutics by 7.2% during the 2nd quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock worth $212,000 after purchasing an additional 480 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares in the last quarter. Finally, American International Group Inc. boosted its position in shares of Kymera Therapeutics by 6.4% during the 1st quarter. American International Group Inc. now owns 20,095 shares of the company’s stock worth $808,000 after purchasing an additional 1,209 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.